Skip to main content
KREDKRED
048410KOSDAQ

Hyundai Bioscience

6,930
-360 (-4.94%)

Price chart

  • MA5
  • MA20
  • MA60

Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.

Market capitalizationKRW 1T

Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.

Overview

Summary

Hyundai Bioscience was established in 2000. The company is listed on the KOSDAQ market and is headquartered in Gyeongsangbuk-do.

The company operates in bio-pharmaceuticals and cosmeceuticals. It develops antiviral treatments and anticancer drugs such as Polytaxel and Penetrium. It also distributes functional cosmetics under the brands Vitabrid C12 and Dr.BRID C to domestic and international markets.

Business overview as filed

현대바이오사이언스는 2000년 5월 25일 현대전자로부터 분사하여 설립된 바이오 제약 및 코스메슈티컬 기업으로 신약 개발과 기능성 화장품 사업을 병행하고 있습니다.

2012년부터 시작한 바이오 사업을 본격적으로 추진하기 위해 기존 IT사업 대부분을 2018년 6월부로 중단하고 같은 해 8월 회사명을 현대바이오사이언스로 변경하였습니다.

현재, 경상북도 김천에 위치한 생산공장과 일본, 미국 등 해외 합작법인 및 자회사를 통해 연구개발(R&D) 및 안정적인 생산·판매망을 구축하고 있으며, 최대주주인 ㈜씨앤팜과 협력하여 범용 항바이러스 치료제 개발과 자체 약물전달 기술을 기반으로 만든 무고통 항암제 폴리탁셀, 기존 항암제의 내성 및 전이를 해결하는 획기적인 약물 흡수 치료제 페니트리움 개발과 이와 관련한 임상시험을 준비하고 있으며 자체 약물전달 기반 기술을 바탕으로 만든 독자적 화장품 브랜드 '비타브리드 C12'를 일본 수출 뿐만 아니라 글로벌 시장을 대상으로 화장품 사업을 확장하고 있으며, 신규 화장품 라인업인 'Dr.BRID C'를 통해 국내 및 글로벌 시장으로 사업을 확장하고 있습니다.

당기 연결재무제표 기준 매출액은 35억원, 영업손실 182억원, 당기순손실 221억원입니다.

Company overview

가. 연결대상 종속회사 개황

(1) 연결대상 종속회사 현황(요약)

(2) 연결대상회사의 변동내용

나. 회사의 법적ㆍ상업적 명칭

회사의 명칭은 현대바이오사이언스 주식회사라 하고, 영문으로는 HYUNDAI BIOSCIENCE CO., LTD.(약호 HDBIO)라 표기합니다.

다. 설립일자

당사는 2000년 5월 25일에 설립되었습니다.

라. 본사의 주소, 전화번호, 홈페이지 주소

(1) 본사의 주소 : 경북 김천시 아포읍 아포공단길 106 (2) 전화번호 : 1544-3194 (3) 홈페이지 : http://www.hyundaibioscience.com

마. 중소기업 등 해당 여부

바. 주요 사업의 내용

당사는 바이오 신약 개발에 집중하여, 범용 항바이러스 치료제 'CP-COV03', 부작용을 최소화한 항암제 '폴리탁셀(Polytaxel)' 그리고 기존 항암제의 내성 및 전이를 해결하는 '페니트리움(Penetrium)' 등의 개발 사업에 주력하고 있습니다.

당사는 국제기구 및 해외 연구단체와의 교류와 공동연구를 통해 신속한 개발을 추진하고 있습니다.

또한 자체 전달 기술을 기반으로 제조되는 고기능성 화장품과 탈모방지 화장품 브랜드인 'Vitabrid C12'의 일본 수출과 해외 유통 확대를 진행하고 있으며 신규 화장품 라인업인 'Dr.BRID C'를 통해 새로운 고객유입 정책과 품목 다변화를 통한 소비자 접점을 확대하여 시장 확대 전략을 추진하고 있습니다.기타의 자세한 사항은 Ⅱ.

사. 신용평가에 관한 사항

당사는 최근 5년간 신용평가를 받은 사실이 없습니다.

아. 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항

Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.30), tables and figures omitted.

  • The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
  • The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.

VaR

5.01%
[2.68%, 9.28%] · As of 2026-10-02
VaR by window

The headline's measure for each of the three windows on one scale, the dot being the estimate and the bar its interval. The windows are nested and share their observations, so the three readings are not three independent measurements. The selected window is highlighted.

Daily return distribution

The issue's daily returns over the chosen window counted into equal-width bins. The vertical lines mark the VaR and cVaR above on the loss side. The published VaR sample applies exclusion rules for halts and first sessions that this raw daily series does not, so the bars and the marks can differ slightly at the edges.

Drawdown

Deepest drawdown 73.6% (2026-07-30). How far below its previous peak the issue stood each day over the chosen window, a description of the path already travelled.

If these numbers are unfamiliarThere is a guide that walks through VaR, cVaR and annualized volatility in plain language.Read the guide

Characteristic line

1.09
Beta [0.87, 1.31] · KOSDAQ150 · As of 2026-10-08
Intercept
+0.169%[-0.429%, +0.767%]
R squared
0.37
Observations
252
Trading-time corrected beta
1.37[0.95, 1.79]
252-day rolling beta

A 252-day window rolled one day at a time over the longest daily span of the characteristic line. It shows when the beta against the KOSDAQ150 and the annualized volatility of the issue's excess return rose and fell, and unlike the headline figures above it carries no interval.

252-day rolling annualized volatility

Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.

Financials

20152016201720182019202020212022202320242025TTM
RevenueKRW 100M4073613203193011259279951513533
Revenue growth%—-11.24-11.44-0.33-5.58-58.41-26.14-15.0420.7658.73-76.63—
Operating incomeKRW 100M14-70151626-45-98-264-988-182-193
Operating income growth%—-613.65—8.1561.43-277.67————-2,396.02—
Net incomeKRW 100M7-8112268-83-201-158-145-69-221-286
Net income growth%—-1,234.60—114.90-70.69-1,176.61——————
Attributable to ownersKRW 100M7-8112268-83-201-158-145-69-221-286
Attributable to minoritiesKRW 100M000000—00000
Operating margin%3.33-19.294.584.978.49-36.29-105.72-335.65-103.205.26-516.32-580.09
Net margin%1.75-22.353.818.222.55-66.02-216.97-201.33-152.92-46.04-629.12-861.51
ROE%2.89-44.313.946.471.63-15.78-32.57-27.14-32.03-17.57-19.98-27.69
ROA%1.64-15.122.464.851.21-8.81-24.90-23.48-27.47-10.23-16.93-21.79
Debt ratio%76.44193.0760.2433.4134.5779.1130.7915.6116.6171.6718.0727.10
Current ratio%351.50135.04196.78312.08238.54466.75209.28286.40218.2724.78225.35236.42
Quick ratio%294.75111.16164.99275.57194.94419.76189.17251.26181.0120.86219.53232.16
Reserve ratio%-170.11-221.40-127.98-68.88-29.04-32.5232.2118.71-48.45-82.8736.517.63
Receivable daysdays—165.3227.6279.1270.1527.5524.6251.141.125.6212.9—
Inventory daysdays—92.2133.5105.8117.2315.8241.3222.3227.5210.0123.3—
Payable daysdays—89.499.260.360.294.9103.1141.9161.0183.4217.9—
Cash conversion cycledays—168.1261.9324.5327.2748.5662.8331.5107.652.2118.3—
EPSKRW23-266377822-230-543-402-365-174-235-296
PERx——142.4369.49638.64———————
BPSKRW—6019481,2011,3561,4571,5931,4681,1379901,1531,070
PBRx—8.825.564.5110.3620.0415.8518.6722.9514.254.317.68
Dividend per shareNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicableNot applicable

Consolidated basis

Profit flowKRW 100M

This fiscal year shows a loss at gross profit, operating income, profit before tax or net income, so it is left to the table rather than drawn as a flow.

This diagram traces where revenue goes at each step on its way to net income, using the filed amounts as they are. The non-operating result is taken as the difference between profit before tax and operating income and is shown as income or expense by its sign, and whatever a step's items leave unexplained is shown separately as other.

Revenue compositionKRW 100M

Margins%

Cash flow by activityKRW 100M

Balance sheet compositionKRW 100M

Debt ratio%

The left bar splits assets into current and non-current and the right bar splits the financing of those assets into liabilities and equity, so the two bars stand at the same height.

Quarterly resultsKRW 100M

Year-on-year growth%

Each quarterly bar is that quarter's three months and is never mixed with an annual figure. The growth rate is computed only where the same quarter a year earlier is also shown here, and is left blank when the base was a loss.

Cash conversion cycledays

Inventory days and receivable days stack upward, payable days hang downward, and the cash conversion cycle they net to is drawn as the line. Each day count uses the average balance with the prior year, so the oldest year is not drawn. A day count whose line was not filed is left out, and the cycle is shown only for years that carry all three.

Owners' net margin%

Asset turnoverx

Financial leveragex

ROE%

ROE is the product of the owners' net margin, asset turnover and financial leverage. All three use period-end balances as denominators, and profit and equity are on the owners' basis, so the product matches the ROE in the table.

Financial statements

Balance sheet

20152016201720182019202020212022202320242025
434534495540632*9378056735286771,307
188352186135162*4141909175283200
246182309405470*5236165824533941,107

Income statement

20152016201720182019202020212022202320242025
407361320319*30112592799515135
14-701516*26-45-98-264-988*-182
9-811228*13*-79-198-166-145-69*-221
7-8112268*-83-201-158-145-69-221
Basic earnings per shareKRW23-26637*7822*-230-543-402-365-174*-235
Diluted earnings per shareKRWNot applicable-266Not applicableNot applicableNot applicableNot applicable-543-402-365-174*-235
7-7813277*-83-201-157-145-67-222

Cash flow statement

20152016201720182019202020212022202320242025
Net incomefrom the income statement7-8112268-83-201-158-145-69-221
Total adjustments to operating cash flowcomputed—————158195-7859251
Not applicableNot applicableNot applicableNot applicableNot applicable75-5-165-6023-170
Not applicableNot applicableNot applicableNot applicableNot applicable-268-1248552-197-386
Not applicableNot applicableNot applicableNot applicableNot applicable3303017-1192744
Cash at beginning of periodKRW 100M221199749325619292271837
1199749325619292271837223
Net change in cash and cash equivalentsKRW 100M97-22-49-1724137-100-65-918187

In the latest fiscal year operations and investing consumed cash raised through financing activities.

A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.

Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.

The newest annual filing shown was received on 2026.03.30.

Audit opinion

Fiscal yearOpinionAuditorFiscal year end
2025적정의견Term 26삼정회계법인2025-12-31
2024적정의견Term 25삼정회계법인2025-12-31
2023적정의견Term 24태성회계법인2025-12-31
2022적정Term 23태성회계법인2022-12-31
2021적정Term 22태성회계법인2022-12-31
2020적정Term 21한울회계법인2022-12-31
2019적정Term 20한울회계법인2019-12-31
2018적정Term 19한울회계법인2019-12-31
2017적정Term 18한울회계법인2019-12-31
2016적정Term 17한울회계법인2016-12-31
2015적정Term 16한울회계법인2016-12-31
2014적정Term 15한울회계법인2016-12-31

The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.

Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.

Valuation

Valuation multiplesx

PER and PBR divide each period's closing price by the per-share figure filed for that same period, and a loss period is left blank. The quarterly view is a multiple of quarterly EPS.

PER bandKRW

The price is the adjusted close and each band line multiplies the EPS of the latest completed fiscal year by a fixed multiple. The previous year's EPS stays in force until the next fiscal year ends, and the multiples divide the range between the lowest and highest annual PER on record into equal steps.

Valuation models

Five models priced under one set of assumptions, set beside the current price, with how each has moved by fiscal year.

Assumptions

Risk-free rate10-year treasury yield · 2026-10-084.40%
BetaDaily 5Y0.87
%
%
Cost of equity8.76%
Weighted average cost of capital—
Initial growth0.0%
Effective tax rate0.0%
Base fiscal year2025
Current priceKRW6,930

The risk premium and the terminal growth rate are adjustable assumptions, and the rest follow from the data and the formulas.

ModelModel priceKRWVersus current price
Gordon growth modelNo dividend
Dividend discount model DDMNo dividend
Discounted cash flow FCFFNo cash flow lines
Discounted cash flow FCFENo cash flow lines
Residual income model RIM-1,099-115.9%
The table prices the newest fiscal year's accounts at today's treasury yield and the current price.

Dividend and residual income familyKRW

Discounted cash flow familyKRW

Each fiscal year's figures use that year's accounts and the treasury yield at its period end, with beta held at its current value, and splits or par changes are restated to the current share basis.

How the figures are calculated

Each model's formula is shown in symbols and then with this issue's own numbers substituted, step by step. Changing a value in the assumptions panel changes the numbers here too. Firm-level amounts are in hundred million won and per-share values in won.

Cost of equity

r=rf+β×ERPr = r_f + \beta \times \mathit{ERP}

r = 4.40% + 0.87 × 5.00% = 8.76%

Initial growth

g1=max⁡{ROE×(1−payout), 0},gt=g1+(gT−g1) t−1N−1g_1 = \max\{\mathit{ROE} \times (1 - \text{payout}),\,0\},\qquad g_t = g_1 + (g_T - g_1)\,\frac{t-1}{N-1}

g_1 = max(-19.98% × (1 − 0.00%), 0) = 0.00%

Growth starts at this value in the first year and falls by equal steps each year to reach the terminal rate in the fifth

Residual income model RIM

P0=B0+∑t=1NRIt(1+r)t+RIN(1+gT)(r−gT) (1+r)N,RIt=(ROE−r) Bt−1P_0 = B_0 + \sum_{t=1}^{N} \frac{\mathit{RI}_t}{(1+r)^t} + \frac{\mathit{RI}_N (1+g_T)}{(r - g_T)\,(1+r)^N},\qquad \mathit{RI}_t = (\mathit{ROE} - r)\,B_{t-1}

B_0 = 1,153 KRW, ROE = -19.98%, payout ratio = 0.00%, r = 8.76%, g_T = 2.00%

YearOpening book valueEarningsEquity chargeResidual incomeDiscount factorPresent value
11,153-230101-3310.9195-305
2923-18481-2650.8454-224
3738-14865-2120.7773-165
4591-11852-1700.7147-121
5473-9441-1360.6571-89
Terminal value-2,0500.6571-1,347

P_0 = 1,153 + -904 + -1,347 = -1,099 KRW

The cost of equity is the risk-free rate plus beta times the equity risk premium. Initial growth is the newest fiscal year's return on equity times its retention ratio, floored at zero, and falls by equal steps from that value in the first year to the terminal rate in the fifth. Only the Gordon model grows at the terminal rate from the start. Discounted cash flow starts from operating cash flow less capital expenditure, where FCFF adds after-tax interest paid and discounts at the weighted average cost of capital, and FCFE adds net borrowing and discounts at the cost of equity. The residual income model adds to book value per share the present value of earnings above the equity charge.

Other issues on the same market

Neighbours in the market capitalisation order.

See the full KOSDAQ list